论文部分内容阅读
Background.Both preclinical data a nd case reports sup-port the use of taxanes for high-risk metastatic choriocar-cinoma.Case.We report the case of a 31-year-old with metastatic choriocarcinoma who req uired 3rd-line treatment with a paclitaxel-cispaltin-based regimen.She achieved a complete response and remains relap se-free 21months after her last dose of chemotherapy.Conclusion.The literaturesuggests that paclitaxel contribut es significantly to the treatment of choriocarcinoma and it s use should be explored further.This is the first case report formally reporting its combinationwith cisplatin.
Background.Both preclinical data a nd case reports sup-port the use of taxanes for high-risk metastatic choriocar-cinoma. Case. We report the case of a 31-year-old with metastatic choriocarcinoma who req uired 3rd-line treatment with a paclitaxel-cispaltin-based regimen. Achieved a complete response and remains relap se-free 21 months after her last dose of chemotherapy. Confluence. The literaturesuggests that paclitaxel contributors significantly to the treatment of choriocarcinoma and it’s use should be explored further.This is the first case report formally reporting its combination with cisplatin.